Marker Therapeutics, Inc. (MRKR)

NASDAQ: MRKR · USD

$1.03

+0.07 (+7.8%)· Recorded snapshot

Market cap	17.1M
Revenue (ttm)	3.5M
Net income (ttm)	-8.7M
EPS (ttm)	-$0.47
Shares out	16.7M
Volume	86,095
Beta	1.53

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.5M
Net income (ttm): -8.7M
EPS (ttm): -$0.47
Market cap: 17.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-76.9

P25 n/aP50 n/aP75 n/a

ROIC-52.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All MRKR indicators

Market & fundamental data

Available fields

203

Groups with data

Currency

USD

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001094038
Company name	Marker Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	57055L206
Earnings date	2026-11-12
Earnings time	amc
Employees	5
Employees change	-3
Employees growth	-37.5%
Enterprise value	$5.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1999
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US57055L2060
Last 10-K release date	2026-03-18
Last earnings date	2026-08-14
Last refreshed	2026-10-28
Last stock split date	2023-01-27
Last stock split type	Reverse
Market cap	$17.1M
Market cap category	Nano-Cap
Next earnings date	2026-11-12
Options	No
Price	$1.03
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	MRKR
U.S. state	Texas
Website	https://markertherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-45.48%
EV/Sales	1.28x
FCF / EV yield	-215.37%
FCF yield	-61.51%
Forward EV/Sales	0.87x
Forward P/S	3.03x
P/B ratio	1.3x
P/S ratio	4.47x
Price / tangible book value	1.3x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-267.95%
Gross margin	-148.28%
Operating margin	-267.95%
Pretax margin	-245.94%
Profit margin	-245.51%
Profit per employee	$-1.7M
Revenue per employee	$709,334
ROA	-40.47%
ROA (5Y)	-35.24%
ROCE	-78.12%
ROE	-76.87%
ROE (5Y)	-79.54%
ROIC	-52.43%
SBC / revenue	14.62%
Tax / revenue	-0.43%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	1
Net income growth quarters	4
Net income growth years	0
Revenue growth	-15.11%
Revenue growth 3Y	-1.89%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-9.5M
EPS	$-0.47
FCF per share	$-0.59
Financing cash flow	$9.9M
Free cash flow	$-9.8M
Free cash flow minus SBC	$-10.3M
Gross profit	$-5.3M
Income taxes	$-15,156
Net cash flow	$107,386
Net income	$-8.7M
Operating cash flow minus SBC	$-10.3M
Operating income	$-9.5M
Revenue	$3.5M
Stock-based compensation	$518,567

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-40.36
Book value per share	$0.73
Debt / equity	0
Long-term assets	$0
Long-term liabilities	$0
Net cash (debt)	$11.3M
Net cash / market cap	71.44%
Net cash growth	8.31%
Net debt / equity	-0.93
Piotroski F-Score	2
Shareholders' equity	$12.2M
Tangible book value	$12.2M
Tangible book value per share	$0.73
Total assets	$14.6M
Total cash	$11.3M
Total debt	$0
Total liabilities	$2.4M
WACC	12.65%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.24
Current assets	$14.6M
Current liabilities	$2.4M
Current ratio	6.03
Net working capital	$834,441
Quick ratio	5.35
Working capital	$12.2M
Working capital turnover	0.31

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-73.22%
Dividend yield	0%
Shareholder yield	-73.22%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-98.07%
10Y return CAGR	-32.63%
10Y total return	-98.07%
150-day SMA	$1.31
15Y price change	-99.96%
15Y return CAGR	-40.88%
15Y total return	-99.96%
1D price change	7.75%
1M price change	-9.57%
1M total return	-9.57%
1W price change	-10.35%
1W total return	-10.35%
1Y price change	1.45%
1Y return CAGR	1.46%
1Y total return	1.45%
20-day SMA	$1.02
200-day SMA	$1.38
20Y price change	-100%
20Y return CAGR	-40.01%
20Y total return	-100%
3M price change	-14.76%
3M total return	-14.76%
3Y price change	-60%
3Y return CAGR	-26.32%
3Y total return	-60%
50-day SMA	$1.16
50-day SMA vs 200-day SMA	50under200
52-week high	$2.46
52-week high date	2026-01-08
52-week low	$0.84
52-week low date	2025-11-10
5Y price change	-93.02%
5Y return CAGR	-41.29%
5Y total return	-93.02%
6M price change	-28.28%
6M total return	-28.28%
All-time high	$6,120,061.20
All-time high date	2002-11-14
All-time low	$0.67
All-time low date	2023-03-31
Average true range (ATR)	$0.12
Average volume	189K
Beta (1Y)	1.78
Beta (2Y)	1.75
Beta (5Y)	1.53
Change from 52-week high	-58.33%
Change from 52-week low	22.02%
Change from all-time high	-100%
Change from all-time low	55.07%
Change from open	7.22%
Day's gap	0.49%
Dollar volume	$88,247
High price	$1.06
Low price	$0.96
Monthly RSI	39.64
Open price	$0.96
Position in 52-week range	66.35%
Premarket change	0.21%
Premarket close	$0.95
Premarket price	$0.95
Premarket volume	1.4K
Previous close	$0.95
Price vs 150-day SMA	-20.8%
Price vs 20-day SMA	2.25%
Price vs 200-day SMA	-24.43%
Price vs 50-day SMA	-10.04%
Relative volume	0.46
RSI	48.79
Sharpe ratio	0.37
Sharpe ratio (3Y)	0.08
Sharpe ratio (5Y)	0
Sortino ratio	0.7
Sortino ratio (3Y)	0.21
Sortino ratio (5Y)	0.07
Volume	86.1K
Weekly RSI	42.59
YTD price change	-30.21%
YTD total return	-30.21%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	13.7M
Float percentage	82.43%
Shares change (QoQ)	0%
Shares change (YoY)	73.22%
Shares held by insiders	7.82%
Shares held by institutions	16.08%
Shares outstanding	16.7M
Short % of float	0.79%
Short % of shares	0.65%
Short ratio	2.5 days

Deeper analysis on MRKR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this MRKR report

Is a complete MRKR research report available?

No complete published report is available for Marker Therapeutics, Inc. (MRKR) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Marker Therapeutics, Inc. (MRKR)

Price

Financial snapshot

Fair-value bridge

Latest news · MRKR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All MRKR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on MRKR

Frequently asked questions